Reported by Gao
et al
(2020)20
| China | 10 hospitals in Wuhan, Jingzhou, Guangzhou, Beijing, Shanghai, Chongqing, and Ningbo | >100 | Unknown |
| Chloroquine phosphate | Unknown |
’
Chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course
’
|
Gautret
et al
(2020)3
| France | Hospitals in Marseille, Nice, Avignon, and Briançon | 36 (20/16) | Treatment: 51.2 (18.7)Control: 37.3 (24.0) |
| 200 mg of Hydroxychloroquine three times a day for 10 days; six patients additionally received azithromycin | Outcome of a nasopharyngeal swab on Day 6 | 70.0% (treatment) versus 12.5% (control) virologically cured, P<0.001 |
Chen
et al
(2020)21
| China | Shanghai Public Health Clinical Centre | 30 (15/15) | Treatment: 50.5 (3.8)Control:46.7 (3.6) |
| 400mg of hydroxychloroquine daily for 5 days | Outcome of a nasopharyngeal swab on Day 7 | 86.7% (treatment) versus 93.3% (control) virologically cured, P>0.05 |